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Complex central nervous system (CNS) malformations frequently coexist with other developmental abnormalities, but whether
the associated defects share a common genetic basis is often unclear. We describe five individuals who share phenotypically
related CNS malformations and in some cases urinary tract defects, and also haploinsufficiency for the NFIA transcription factor
gene due to chromosomal translocation or deletion. Two individuals have balanced translocations that disrupt NFIA. A third
individual and two half-siblings in an unrelated family have interstitial microdeletions that include NFIA. All five individuals
exhibit similar CNS malformations consisting of a thin, hypoplastic, or absent corpus callosum, and hydrocephalus or
ventriculomegaly. The majority of these individuals also exhibit Chiari type I malformation, tethered spinal cord, and urinary
tract defects that include vesicoureteral reflux. Other genes are also broken or deleted in all five individuals, and may contribute
to the phenotype. However, the only common genetic defect is NFIA haploinsufficiency. In addition, previous analyses of Nfia/
knockout mice indicate that Nfia deficiency also results in hydrocephalus and agenesis of the corpus callosum. Further
investigation of the mouse Nfiaþ/ and Nfia/ phenotypes now reveals that, at reduced penetrance, Nfia is also required in a
dosage-sensitive manner for ureteral and renal development. Nfia is expressed in the developing ureter and metanephric
mesenchyme, and Nfiaþ/ and Nfia/mice exhibit abnormalities of the ureteropelvic and ureterovesical junctions, as well as bifid
and megaureter. Collectively, the mouse Nfia mutant phenotype and the common features among these five human cases
indicate that NFIA haploinsufficiency contributes to a novel human CNS malformation syndrome that can also include ureteral
and renal defects.
Citation: Lu W, Quintero-Rivera F, Fan Y, Alkuraya FS, Donovan DJ, et al (2007) NFIA haploinsufficiency is associated with a CNS malformation syndrome and urinary tract
defects. PLoS Genet 3(5): e80. doi:10.1371/journal.pgen.0030080
Introduction
Complex human developmental phenotypes represent an
especially difficult problem in human genetics. In many cases,
congenital birth defects are believed to result from the
combined effect of many genes, often with an environmental
contribution, and frequently culminate in perinatal demise.
Thus, for many cases, extended families do not exist, and
approaches to disease gene identification based on linkage
analysis are not possible. In addition, many developmental
disorders are genetically heterogeneous, making the ascer-
tainment of single contributory genes difficult.
The analysis of human balanced chromosome rearrange-
ments offers a potential approach to this problem. Although
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unforeseen rearrangements and position effects may super-
vene [1,2], and a background rate of birth defects exists,
human translocations provide powerful tools to identify
genes that are essential to human development. Trans-
locations may result in haploinsufficiency, the generation of
fusion transcripts, or position effects, or act in combination
with a second loss-of-function allele. The Developmental
Genome Anatomy Project, DGAP (http://dgap.harvard.edu),
has as its specific goal the ascertainment, recruitment, and
analysis of individuals with chromosomal rearrangements and
developmental disorders. A conspicuous class of such
disorders is that involving the formation of the CNS and
visceral organs.
Within the CNS, the corpus callosum is the largest
interconnecting white matter tract in the brain, and it
connects the association fibers of both hemispheres. Agenesis
of the corpus callosum (ACC) is among the most common
brain malformations in humans, with an incidence of 1 per
4,000 live births [3–5] and a prevalence as high as 3%–5% in
individuals with neurodevelopmental disabilities [6,7]. In
human embryos, the corpus callosum begins to develop at
11–12 wk gestation when the first fibers cross the midline to
form the genu in the region of the commissural plate, and
subsequent development proceeds from anterior to posteri-
or, with formation of the anterior body, posterior body, and
splenium, followed by a progressive enlargement that reflects
the rapid expansion of the cerebral hemispheres [8].
Abnormalities of the corpus callosum can occur through a
number of mechanisms, including defects in the genesis or
survival of neuronal cells whose axons form the corpus
callosum, and defects in axonal outgrowth, pathfinding, and
midline crossing [9]. The etiology of ACC is thus heteroge-
neous and multifactorial, and both autosomal recessive and
X-linked recessive mechanisms have been described [9] (see
also Online Mendelian Inheritance in Man [OMIM, http://
www.ncbi.nlm.nih.gov/entrez/query.fcgi?db¼OMIM]). ACC is
associated with certain chromosomal rearrangements [9] and
occurs as a component of other genetic syndromes [10] and
metabolic conditions [11], but its genetic heterogeneity and
phenotypic pleiotropy have limited identification of the
responsible genes to only a few of the more than 20 distinct
loci that are associated with ACC, including one on the short
arm of Chromosome 1 [12].
In addition to other CNS defects with which ACC is
frequently associated, ACC may occur in conjunction with
visceral organ malformations. For example, ACC and its
associated brain and spinal cord lesions have been linked to
vesicoureteral reflux (VUR), cystic kidney disease, renal
agenesis and insufficiency, and neurogenic lower urinary
tract dysfunction, a condition that includes neurogenic
bladder and VUR [13–16]. Alternatively, single gene muta-
tions may produce developmental defects in both the CNS
and urinary tract. We show here that a novel human
syndrome involving both CNS and urinary tract defects is
associated with disruption or deletion of the NFIA gene at
1p31.3, which encodes a member of the Nuclear Factor I (NFI)
family of transcription factors [17]. Disruption of Nfia in mice
results in perinatal lethality, hydrocephalus, and ACC [18],
and a recent study shows that NFIA controls the transition
from neurogenesis to gliogenesis in the developing spinal
cord [19]. Similar studies indicate that two other Nfi family
members, Nfib and Nfic, are essential for lung, brain and tooth
development [20,21]. However, the role that NFI transcrip-
tion factors play in human disease has been unknown. Our
results establish that NFIA haploinsufficiency is a likely
contributor to a range of CNS defects, including ACC,
hydrocephalus, ventriculomegaly, Chiari type I malformation,
and tethered spinal cord, and that renal defects can also
result from a disturbance in ureteral development.
Results
CNS and Urinary Tract Defects in Individuals with 1p31
Rearrangements
We investigated five individuals enrolled in DGAP (i.e.,
DGAP104, 089, 174, 205–1, and 205–1s), each with a similar
spectrum of CNS defects, and in three cases, of urinary tract
defects. All five individuals had chromosomal rearrangements
that variously involved 1p31. DGAP104 is a 6-y-old female
diagnosed at birth with congenital hydrocephalus, a thin
corpus callosum, Chiari I malformation, tethered spinal cord,
and a low vertebral deformity (Figure 1A, 1B, and 1K). She
was also found to have congenital bilateral dysplastic kidneys,
and subsequently developed bilateral VUR, pyelonephritis, a
ureterovesical junction diverticulum, and hydronephrosis,
and required ureteral reimplantation surgery at age 2 y
(Figure 1L; Tables 1 and S1). Chromosome analysis in the
neonatal period revealed an apparent de novo balanced
chromosome translocation between 1p31 and 20q13.
A second individual, DGAP089, is an 8-y-old male whose
clinical profile was described previously (Table 1, S1) [22]. He
has both an interstitial deletion on 2q and a balanced
translocation involving 1p and 2q [22]. As an infant, he had
poor fetal movement, and a CT scan revealed a vertical
orientation of the ventricles consistent with a primary defect
of the corpus callosum. At age 2 y, a CT scan revealed
ventriculomegaly, and at age 6.5 y a brain MRI showed a
hypoplastic corpus callosum, nonprogressive ventriculome-
galy, and a gray matter heterotopia (Figure 1C and 1D; Tables
1 and S1). Renal ultrasound revealed no major abnormalities,
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Author Summary
Central nervous system (CNS) and urinary tract abnormalities are
common human malformations, but their variability and genetic
complexity make it difficult to identify the responsible genes.
Analysis of human chromosomal abnormalities associated with such
disorders offers one approach to this problem. In five individuals
described herein, a novel human syndrome that involves both CNS
and urinary tract defects is associated with chromosomal disruption
or deletion of NFIA, encoding a member of the Nuclear Factor I (NFI)
family of transcription factors. This syndrome includes brain
abnormalities (abnormal corpus callosum, hydrocephalus, ventricu-
lomegaly, and Chiari type I malformation), spinal abnormalities
(tethered spinal cord), and urinary tract abnormalities (vesicoureteral
reflux). Nfia disruption in mice was already known to cause
hydrocephalus and abnormal corpus callosum, and is now shown
to exhibit renal defects and disturbed ureteral development. Other
genes besides NFIA are also disrupted or deleted and may
contribute to the observed phenotype. However, loss of one copy
of NFIA is the only genetic defect common to all five patients. The
authors thus provide evidence that genetic loss of NFIA contributes
to a distinct CNS malformation syndrome with urinary tract defects
of variable penetrance.
but a definitive evaluation for urinary reflux (i.e., a voiding
cystourethrogram, or VCUG) was not performed.
A third individual, DGAP174, who exhibited complete ACC
and enlarged ventricles by second trimester ultrasound, had
both a de novo translocation of 1p31.1 and 3q25.1 and an
interstitial deletion of 1p31. A postnatal brain CT scan
confirmed these findings and also revealed ventriculomegaly
and a tethered spinal cord. A brain MRI at age 3 y revealed a
Chiari type I malformation and dysplasia of the anterior left
temporal fossa, in addition to ventriculomegaly and ACC
(Figure 1E and 1F; Tables 1 and S1). As with DGAP089, no
major renal abnormalities were detected by ultrasound, and
VCUG was not performed.
Lastly, we ascertained two previously described half-
siblings who shared CNS and renal phenotypes similar to
those in DGAP104 [23]. Both individuals, DGAP205–1 and
DGAP205-1s, have a maternally inherited, unbalanced inter-
stitial microdeletion, del(1)(p31.3p32.3), and exhibited an
abnormal corpus callosum, congenital hydrocephalus, syrin-
gomyelia, tethered spinal cord, and urinary tract phenotypes
including VUR (Figure 1G–1J and 1M–1O) [23].
Cytogenetic and Genetic Analyses of the Chromosomal
Rearrangements
To determine whether a common genetic defect underlay
the phenotypes of these individuals, we analyzed the 1p31
region in all five patients and found that the NFIA gene was
either disrupted or deleted in each case. DGAP104 has a de
novo balanced translocation, 46,XX,t(1;20)(p31.3;q13.31)dn
(Figure 2A, 2B). By metaphase fluorescence in situ hybrid-
ization (FISH), we identified a bacterial artificial chromosome
(BAC) clone (RP4-802A10) that mapped to 1p31.3 and
hybridized to the breakpoints of the der(1) and der(20)
chromosomes (Figure 2C). The translocation breakpoint at
1p31.3 disrupts intron 2 of NFIA, which is composed of 11
Figure 1. CNS and Urinary Tract Defects in Five Individuals with 1p31.3 Rearrangements
(A–J) Brain CT or MRI show a thin corpus callosum in DGAP104 (arrow in A), DGAP089 (arrow in C), and DGAP205–1 (arrow in G); and agenesis of the
corpus callosum in DGAP174 (asterisk in E) and DGAP205-1s (asterisk in I). Chiari type I malformation, a downward displacement of the tip of the
cerebellar tonsils below the foramen magnum, was found in DGAP104 (arrowhead in A), DGAP174 (arrowhead in E), and DGAP205-1s (arrowhead in I).
Congenital ventriculomegaly is present in DGAP089 (D), DGAP174 (F), and DGAP205-1s (J), and hydrocephalus was found in DGAP104 (B) and
DGAP205–1 (H). An occipital shunt (arrow in B) was placed in DGAP104 to relieve severe hydrocephalus.
(K) DGAP104 MRI shows a tethered spinal cord, with the extremity of the conus medullaris (arrow) at the level of the L4 vertebral body. Arrowhead
shows a fishhook deformity of the lower sacral and coccygeal vertebrae.
(L) VCUG of DGAP104 depicts left vesicoureteral reflux with retrograde tracking of dye through the ureter into the renal pelvis (arrow) and a right
diverticulum at the ureterovesical junction (arrowhead).
(M) Spine MRI of DGAP205–1 shows a tethered spinal cord with conus lying at the L3/L4 level (arrow).
(N) VCUG of DGAP205–1 shows left vesicoureteral reflux (arrow).
(O) Spine MRI of DGAP205-1s depicts a tethered spinal cord with conus lying at L5 (arrow).
doi:10.1371/journal.pgen.0030080.g001
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exons and spans ;374 kb of genomic DNA (Figure 2I). This
result was confirmed by Southern blot analysis (Figure S1).
In addition to disruption of NFIA at 1p31.3 in DGAP104,
C20orf32 was also disrupted by the 20q13.31 breakpoint. A
contribution of C20orf32 disruption to the spinal and kidney
phenotypes in DGAP104 is unlikely, however, because
C20orf32 expression was not detected in the developing
spinal cord or kidney by in situ hybridization (Figure S2). By
array comparative genomic hybridization (aCGH), we ex-
cluded any additional chromosome abnormalities in
DGAP104 at ;1 Mb resolution.
For DGAP089, sequential FISH led to identification of a
1p31.3 breakpoint-spanning BAC, RP5-902P15, which hybri-
dized to Chromosome 1 and to both der(1) and der(2)
chromosomes (Figure 2D). Subsequent FISH and Southern
blot analyses (Figure S3) refined the breakpoint to ;3.9 kb
between exons 7 and 8 of NFIA (Figure 2I). Similar analyses of
the 2q breakpoint revealed a split signal for BAC RP11-745P9,
thus localizing the breakpoint to ;138 kb in 2q22.1, which
contains no annotated genes. However, metaphase FISH
followed by aCGH at ;1 Mb resolution revealed a ;12-Mb
interstitial deletion in 2q proximal to the 2q translocation
breakpoint, for which the karyotype is 46,XY,t(1;2)
(p31.3;q22.1),del(2)(q14.3q21)dn. The 39 genes within this
deletion interval may thus also contribute to the DGAP089
phenotype [22].
To establish further whether disruption of NFIA is
primarily associated with the congenital CNS anomalies
observed in DGAP104 and DGAP089, we next investigated
DGAP174, who has both a t(1;3)(p31.1;q25.1)dn and an
interstitial deletion, del(1)(p31.3p32.1)dn. The 1p31.1 and
3q25.1 translocation breakpoints were refined to 150 and 180
kb, respectively. The only other potentially relevant gene in
these intervals is NEGR1, which is disrupted by the 1p31.1
breakpoint. In rat, NEGR1 protein is expressed only after
E16, with peak expression occurring postnatally, after corpus
callosum formation [24]. However, by RT-PCR, NEGR1
transcript is expressed in human cerebral cortex, hippo-
campus, corpus callosum, and cerebellum (unpublished data);
hence, a contribution to the DGAP174 CNS phenotype is
possible. On the other hand, the chromosome deletion in
DGAP174, which was delimited by FISH and aCGH to 2.2 Mb
at 1p31.3–1p32.1 (Figures 2E and S4), also results in the
complete deletion of NFIA and of eight additional genes
(Figure 2I).
Lastly, we performed metaphase FISH analyses on chro-
mosomes isolated from the two half-siblings DGAP205–1 and
DGAP205-1s and their mother DGAP205–2 (Figure 2F–2I).
The 1p31.3–1p32.3 region, encompassing ;12 Mb and
containing the entire NFIA gene and ;47 additional genes,
is deleted in both DGAP205–1 and DGAP205–2 (Figure 2G–
2I). The mother, DGAP205–2, is phenotypically normal but
has an apparent balanced rearrangement in which
1p31.3p32.3 is inserted into Chromosome 4 with no loss of
genetic material, and her karyotype is therefore designated
46,XX,ins(4;1)(q35;p31.3p32.3) (Figure 2H) [23].
NFIA Haploinsufficiency Is Common to All Five Cases
All five individuals share strikingly similar CNS pheno-
types, including abnormalities of the corpus callosum,
hydrocephalus, and ventriculomegaly. All also share disrup-
tion or deletion of NFIA, and in each case, the nonrearranged
or nondeleted NFIA allele was subjected to DNA sequencing
and no mutations were identified (unpublished data). There-
fore, all five cases have NFIA haploinsufficiency in common.
NFIA is highly expressed in multiple regions of the human
brain, including the embryonic and adult corpus callosum
(Figure S5) [25], and ACC and hydrocephalus were observed
in Nfia/ mutant mice [18].
In each DGAP case, one or more additional genes were also
directly affected as a consequence of either the translocation
or deletion. These additional genes may contribute to or
modify the nature of the phenotype attributable to NFIA
disruption or deletion. However, the identities of these genes
differ among the five DGAP cases, except for 205–1 and 205–
1s, who share the same 12-Mb deletion; and 205–1, 205–1s,
and 174, who share a common 2.2-Mb deletion region (Figure
2I). C20orf32 is disrupted in addition to NFIA in DGAP104,
whereas in DGAP089 disruption of NEGR1 and deletion of 39
genes in del(2)(q14.3q21) occurred. Besides the disruption or
deletion of NFIA, none of the other of these genetic
aberrations is shared by more than three cases. Therefore,
Table 1. Common Clinical Features in Five Individuals with NFIA Haploinsufficiency
Clinical
Features
DGAP089 DGAP104 DGAP174 DGAP205–1 DGAP205-1s
Karyotype 46,XY,t(1;2)
(p31.3;q22.1),
del(2)(q14.3q21)dn
46,XX,t(1;20)
(p31.3;q13.31)dn
46,XY,t(1;3)(p31.1;q25.1),
del(1)(p31.3p32.1)dn
46,XY,del(1)(p31.2p32.3)mat 46,XX,del(1)(p31.2p32.3)mat
Phenotype Abnormal corpus
Callosum
þ þ þ þ þ
Ventriculomegaly
or hydrocephalus
þ þ þ þ þ
Developmental delay þ þ þ þ þ
Tethered spinal cord nd þ þ þ þ
Chiari I malformation nd þ þ  þ
Seizures þ þ nd þ nd
Urinary tract defects nd þ nd þ þ
nd, not determined
doi:10.1371/journal.pgen.0030080.t001
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Figure 2. NFIA is Deleted or Disrupted in All Five Individuals with 1p31.3 Rearrangements
(A and B) Partial karyogram (A) and ideogram (B) of DGAP104 show the chromosome translocation t(1;20)(p31.3;q13.31)dn.
(C) FISH analysis of DGAP104; BAC RP4-802A10 (red signals) hybridizes to the normal Chromosome 1 and der(1) and der(20) chromosomes, thus
spanning the 1p31.3 breakpoint.
(D) FISH analysis of DGAP089 depicts BAC RP5-902P15 (red signals) hybridization to the normal Chromosome 1 and der(1) and der(2) chromosomes,
thus spanning the 1p31.3 breakpoint.
(E) FISH analysis reveals that BAC RP5-902P15 (overlapping with NFIA, orange color) is deleted from the der(1) in DGAP174. The nondeleted BAC RP11-
134C1 (green) is present on both the normal and derivative Chromosome 1.
(F) DGAP205 pedigree with NFIA deletion (arrow indicates the DGAP205–1 proband). DGAP205–1 and half-sister DGAP205-1s have an unbalanced
interstitial microdeletion, del(1)(p31.3p32.3), while their phenotypically normal mother DGAP205–2 has a balanced chromosome rearrangement due to
an insertion of 1p31.3-p32.3 into Chromosome 4, ins(4;1)(q35;p31.3p32.3). del-NFIA, deletion of NFIA; ins-NFIA, insertion of NFIA.
(G and H) FISH analyses show that BAC RP5-902P15 (overlapping with NFIA, orange color) is absent from the der(1) in DGAP205–1 (G) and der (1) in the
mother DGAP205–2 (H), but present in the der(4) in the latter (H). The nondeleted BAC RP4-654H19 (green) is present on both the normal and derivative
Chromosome 1.
(I) NFIA exon–intron structure is shown in the upper part with select exons numbered, and the relevant BAC contig below. Locations of the 1p31.3
translocation breakpoints in DGAP104 and DGAP089 are indicated by red dotted vertical lines. The lower part of (I) depicts 1p31.3–1p32.3 genomic
regions with the cytogenetic bands on the short arm of Chromosome 1. TEL represents telomeric orientation, and CEN represents centromeric
orientation. Known genes in this region are represented by dots and gene names. FISH-verified BAC clones are represented by horizontal bars. The full
names of the BAC clones are listed in Materials and Methods. A 2.2-Mb genomic region deleted in DGAP174 and a ;12-Mb genomic region deleted in
DGAP205–1 and 205–1s are shown. Deleted BAC clones tested by FISH are designated in red and nondeleted clones in blue. BAC 802A10 overlaps with
NFIA and is deleted.
doi:10.1371/journal.pgen.0030080.g002
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the most parsimonious explanation for the observed CNS
phenotypes is NFIA haploinsufficiency, which is the only
common genetic defect shared by all five individuals.
To test whether intragenic mutations in NFIA are associ-
ated with abnormal callosal development and other CNS
phenotypes, we sequenced the 11 exons and intron-exon
boundaries of NFIA in 84 patients with various combinations
of syndromic CNS phenotypes, including abnormal corpus
callosum, tethered spinal cord, Chiari I malformation,
hydrocephalus, and urinary tract defects (Table S2). Sequence
analysis was also performed on a group of 96 individuals that
included both syndromic and nonsyndromic ACC, and on
another group of 39 individuals with nonsyndromic tethered
cord syndrome. Although several known SNPs were detected,
no intragenic mutations were identified. Thus, intragenic
mutation in NFIA is not a frequent cause of the CNS defects
described here.
Further Analysis of Mouse Nfia Mutants Reveals Additional
Phenotypes
To gain further evidence for the assignment of NFIA as the
gene responsible for the CNS and urinary tract defects
observed in the five individuals, we re-investigated the
previously described Nfia/ knockout mouse [18]. Because
syringomyelia, a persistent patency of the central canal within
the spinal cord, is often associated with Chiari type I
malformation [26] and was observed in DGAP205-1s but not
previously noted in Nfia/ mice [18], we first examined Nfia
expression in the developing spinal cord (Figure 3A–3D).
From E11.5–13.5, the expression of Nfia in the spinal cord
moves dynamically from rostral to caudal as development
proceeds, coincident with the timing of central canal closure
(Figure 3A, 3B). Moreover, Nfia expression resides in the basal
ventricular zone surrounding the central canal (Figure 3C,
3D). Four of six (66%) Nfia/ newborns exhibited syringo-
myelia that was manifest as an enlarged central canal and
principally confined to the lumbar region (Figure 3E, 3F).
Syringomyelia has been proposed to result from progressive,
mechanical overload and dissection of the rostral spinal cord
by elevated cerebral spinal fluid hydrostatic pressure such as
that associated with hydrocephalus [27]. Indeed, all five
individuals with NFIA haploinsufficiency exhibited hydro-
cephalus or ventriculomegaly. However, mouse Nfia expres-
sion in the spinal cord surrounds the central canal and
defective canal closure in Nfia/ mutants precedes the
development of hydrocephalus. This suggests that syringo-
myelia may result from a developmental defect in the
dynamic process of canal closure.
Nfia Expression and Abnormal Kidney Development in
Nfia Mutants
DGAP104, 205–1 and 205–1s share similar urinary tract
phenotypes. Although the CNS defects in all five individuals
are consistent with findings in mouse Nfia mutants [18], it
remained possible that the urinary tract defects might result
from the genetic lesion at 20q13.31 (in DGAP104), from
haploinsufficiency for other genes in the 1p31.3-p32.3
deletion interval (in DGAP205–1 and DGAP205-1s), or from
incidental mutations in other loci. Previously, it was noted
that Nfia homozygotes died shortly after birth [18]. Based
upon prior experience with mouse mutants with renal
agenesis and dysplasia [28–32], we hypothesized that some
part of this perinatal lethality might be explained by defects
in renal development.
To determine whether the urinary tract phenotypes in
DGAP104, 205–1, and 205–1s were linked to NFIA disruption,
we investigated Nfia expression in the developing murine
kidney and renal morphology in Nfia/ mice. By in situ
hybridization, Nfia was abundantly expressed in the develop-
ing nephric duct and metanephros from E9.5 to E16.5,
correlating with the stages of ureteric bud outgrowth,
Figure 3. Nfia Spinal Cord Expression and Syringomyelia Phenotype in
Nfia/ Mice
(A and B) Whole mount in situ hybridization shows abundant Nfia
expression in the spinal cord (arrow) of E12.5 (A) and E13.5 (B) mouse
embryos. The expression maximum (arrow) transits from rostral to caudal
as development proceeds.
(C and D) Nfia expression is restricted to the floor plate and spinal
ganglia at E11.5 (C), and to the ventral spinal cord at E13.5 (D).
(E and F) Spinal cord phenotype in Nfia E18.5 embryos. (E) The lumbar
spinal cord central canal is nearly obliterated in wild-type embryos,
whereas (F) shows persistent dilation of the lumbar spinal cord central
canal (syringomyelia, arrow) in E18.5 Nfia/ mutants.
doi:10.1371/journal.pgen.0030080.g003
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metanephric induction, and rapid nephron morphogenesis;
expression began to be downregulated at E17.5 (Figure 4A–
4I). At E9.5, Nfia expression appeared in the nephric duct and
persisted at E10.5 and 11.5 in the developing ureter,
becoming more restricted to the distal ureter by E12.5
(Figure 4A and 4B). Nfia was expressed in both ureteric bud
epithelium and the surrounding mesenchyme at these time
points (Figure 4E and 4F). By E16.5, Nfia expression became
restricted to stromal mesenchyme, and was downregulated a
day later (Figure 4C, 4D, 4G, and 4H).
We next examined the kidney morphology of Nfia/
newborn mice. Remarkably, 13 of 19 (68%) Nfia/ newborns
displayed agenesis, dysplastic, cystic, or duplex kidneys
(Figure 5A–5K). A small number of Nfia/mutants exhibited
a partial duplex kidney phenotype. This was apparent from
both the elongated kidney morphology with a central
constriction, and from histological evidence of an ectopic
nephrogenic zone that demarcated discrete rostral and
caudal nephric poles (Figure 5D, 5H, and 5I).
The presence of kidney defects was not confined to Nfia/
mutants. Four of 18 (22%) of Nfiaþ/ newborn mice also
expressed hydronephrosis (Figure 5B). The possibility that
these Nfiaþ/ newborns might be Nfia/ mice that were
misgenotyped was excluded because the Nfiaþ/ affecteds
were offspring of an Nfiaþ/3 Nfiaþ/þ cross. The sensitivity of
mouse kidney development to Nfia gene dosage supports the
conclusion that kidney defects can occur in humans carrying
disruption or loss of a single NFIA allele. Therefore,
disruption or deletion of NFIA in DGAP104, 205–1, and
205–1s likely explains the kidney phenotypes observed in
these individuals.
We next sought to characterize further the renal defects in
Nfia/ embryos by marker experiments. Markers analyzed
included Wt1 (glomerular podocytes), DBA (distal tubule and
collecting duct), LTL (proximal tubule), and E-cadherin (cell
adhesion and aggregation). No consistent changes from wild
type that would reflect a deficiency of a particular cell type
were observed (unpublished data). These results suggest that
the renal defects in Nfia mutants are not lineage- or segment-
specific.
Nfia Kidney Defects Involve Defective Ureteral
Development
The relative preservation of tubular and glomerular
markers in Nfia mutant kidneys, the diverse spectrum of
renal abnormalities, and the presence of hydronephrosis
suggested that the renal parenchymal changes might be
secondary to ureteral reflux or obstruction. To test this
hypothesis, we crossed a Hoxb7 promoter-directed GFP
reporter allele into the Nfiaþ/ and Nfia/ backgrounds. The
Hoxb7-GFP transgene is specifically expressed in ureteral
epithelium as early as E10.5, and thereafter in the ureteric
Figure 4. Nfia Expression in the Developing Mouse Urinary Tract
(A–D) Whole mount in situ hybridization shows Nfia expression in the developing nephric duct (arrow in A), ureter (arrow in B), and metanephros
between E9.5 (not shown) and E16.5, becoming downregulated at E17.5. Reticular pattern of Nfia expression is in the kidney from E14.5–16.5 (C). (E–H)
Section in situ hybridizations shows Nfia expression in the ureteral epithelium (arrow in F) and surrounding mesenchyme (arrowhead in F) at E11.5 (F is
the enlarged view of boxed region in E), and in stromal mesenchyme (arrows in G and H) at E16.5–17.5.
(I) RT-PCR of the developing mouse kidney showing that Nfia is abundantly expressed up to E16.5 and begins to be downregulated at E17.5. b-actin is
used as RNA loading control.
NB, newborn.
doi:10.1371/journal.pgen.0030080.g004
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bud and its derivatives, and eventually in renal tubular
epithelium [33].
Remarkably, when assayed by GFP expression, four of 20
(20%) Nfiaþ/ and two of six (33%) Nfia/ newborns exhibited
clear abnormalities of ureteral development (Figure 6A–6F).
These abnormalities fell into three classes. First, we observed
a partial duplication of the ureter (Figure 6C), which
correlates with the duplex kidney phenotype. A second class
Figure 5. Spectrum of Kidney Phenotypes in Nfia/ Newborn Mice
Whole mounts of dissected urinary tracts from newborn mice of the indicated genotype (A–F). Normal wild-type newborn kidney and renal histology (A
and G); (B) rare Nfiaþ/ showing hydronephrosis (arrow); (C–F and H–K) Nfia/ mutants showing bilateral renal agenesis (arrow in C), an elongated,
partial duplex kidney with the abnormal cortical zone that demarcates the two poles shown with an arrow (D, H, and I), severely dysplastic kidney with
irregular renal surface (arrow in E) and disorganized renal parenchyma (E and J), and nodular Nfia homozygous newborn kidney (F) with renal tubule
cystic dilatation (K).
doi:10.1371/journal.pgen.0030080.g005
Figure 6. Nfia is Required for Normal Ureteral Development
A Hoxb7-GFP transgenic reporter in the Nfiaþ/ and Nfia/ backgrounds reveals ureteral defects in newborn mice.
(A–D) Wild-type and Nfiaþ/ newborns with megaureter (with extent of dilation indicated by two-headed arrow) (A, C) and partial ureteral duplication
(arrow) in the mutant (C). Higher power views of boxed areas in (A) and (C), showing distortion of the mutant ureter at the UVJ (B and D); note that the
vas deferens in the Nfiaþ/ male (C) is also GFP–positive.
(E and F) Abnormalities in Nfia/ newborns include proximal flexion of the ureter (E) and dysplastic kidney (F).
k, kidney; t, testis; ur, ureter; UVJ, ureterovesical junction; v, vas deferens
doi:10.1371/journal.pgen.0030080.g006
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consisted of mutant ureters that were dilated, either as a
consequence of obstruction or from reflux (Figure 6C and
6D). In the third class, we observed abnormal flexure of the
rostral ureter, with the site of flexion near the renal pelvis
(Figure 6E), which could lead to obstruction. To determine
whether prolonged reflux and obstruction in Nfia/ mutants
affected postnatal kidney development, we analyzed two rare
Nfia/ postnatal survivors. Both P16 Nfia/ developed severe
hydronephrosis, whereas kidneys in their wild-type litter-
mates were normal (Figure S6).
Lastly, we analyzed the histology of two key ureteral
structures, the ureteropelvic junction (UPJ), which connects
the ureter to the kidney, and the ureterovesical junction
(UVJ), which connects the ureter to the bladder. Both UPJ
and UVJ histological defects were noted in Nfiaþ/ newborns,
while only UPJ defects were identified in Nfia/ newborns
(Figure 7A–7F). The presence of UPJ and UVJ dilation in Nfia
mutant mice (Figure 7B, 7C, and 7E) is consistent with the
observations of VUR and hydronephrosis in DGAP104, 205–1,
and 205–1s. Thus, abnormalities in ureteral development
comprise a significant part of the Nfia mutant phenotype.
Moreover, because proper formation of the vertebrate kidney
depends upon induction by the ureteric bud, ureteral
abnormalities could account for aspects of the kidney defects
in NFIA haploinsufficient patients and mutant mice.
Discussion
NFIA Haploinsufficiency as a Pathogenetic Mechanism
The five individuals studied here share NFIA haploinsuffi-
ciency caused by translocation (DGAP089 and 104) or
deletion (DGAP174, 205–1, and 205–1s). All five also share
abnormalities of the corpus callosum, and partly share other
CNS phenotypes, including ventriculomegaly, congenital
hydrocephalus, Chiari type I malformation, and tethered
spinal cord. All five individuals also have developmental delay
and three exhibited seizure disorders. Three of the five also
have urinary tract defects, including VUR. Prior work
established that Nfia loss of function in the mouse results in
ACC and abnormal development of the hippocampal
commissure, two major axonal tracts that connect the
cerebral hemispheres, and an associated hydrocephalus that
develops in rare postnatal survivors [18,34]. We also found
that the mouse Nfia mutant recapitulates the VUR phenotype
in these humans. Therefore, although other affected genes
may contribute to the overall phenotype, these cases suggest
that NFIA haploinsufficiency can account for the observed
CNS and renal defects.
It is important to acknowledge that a contribution to the
developmental phenotypes identified here from additional
genes that reside within various deletion intervals, or that
also suffer disruption by breakpoints, is not excluded. In all
five cases, additional genes besides NFIA are also disrupted or
deleted, so that in no single case is a defect in NFIA the only
genetic abnormality. While DGAP104 only inactivates NFIA
and C20orf32 and the latter is an unlikely contributory factor,
the most extreme cases are DGAP089 and the DGAP205 half-
siblings, which contain deletions that involve 39 and 47 genes,
respectively. Because these two deletions involve different
chromosomes, none of the deleted genes are shared. How-
ever, in both cases, many more genes are affected than just
NFIA, and some may participate in the observed phenotypes.
For example, two cases described in the literature report 2q
deletions that overlap with the del(2)(q14.3q21) in DGAP089,
and these also involve ACC [35,36]. Therefore, in the absence
of intragenic mutations in NFIA, the definitive argument that
NFIA is the gene responsible for the CNS and renal
phenotypes in these five patients cannot be made.
The inability to identify intragenic mutations in NFIA in
cases involving ACC, hydrocephalus, tethered cord syndrome,
and urinary tract defects could suggest that the phenotype of
heterozygous intragenic loss-of-function NFIA mutations
might differ from that described here. Indeed, as noted, it
is quite plausible that in any individual DGAP case, the
Figure 7. Ureter Defects at UPJ and UVJ in Nfia Mutant Mice
(A–C) Hematoxylin and eosin histology depicts duplication and dilatation of ureter at the UPJ in Nfiaþ/ (B, 60X) and Nfia/ (C, 60X) newborn mice.
(D–F) Hematoxylin and eosin staining shows dilatation of UVJ in some Nfiaþ/mutant mice (* in E, 60X); the majority of Nfiaþ/ and Nfia/mice show a
normal UVJ (F, 60X).
a, abdominal aorta; bl, bladder; pe, pelvis; r, rectum; ur, ureter; UVJ, ureterovesical junction
doi:10.1371/journal.pgen.0030080.g007
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observed phenotype represents the additive effect of NFIA
haploinsufficiency plus other loci that are deleted or
disrupted. On the other hand, at least 20 discrete loci have
been implicated in ACC alone, so that the failure to detect
intragenic mutations in NFIA is not surprising. Ultimately,
formal definition of the NFIA hemizygous loss-of-function
phenotype would be strengthened by identification of intra-
genic loss-of-function NFIA mutations.
Lastly, it is well recognized that both chromosomal trans-
locations and deletions may engender position effects that
alter gene expression at considerable distances from the site
of a chromosomal aberration (reviewed in [1,2]). For example,
Shh expression in the limb bud mesenchyme is controlled by a
regulatory region located ;1 Mb upstream within the
unrelated Lmbr1 gene [37]. Position effects on neighboring
genes for mouse knockouts have been described [38]. The
mouse Nfia mutant results from a small exon 2 deletion, yet
still accurately recapitulates many features of the human
phenotype. Therefore, one would have to posit the existence
of a conserved regulatory element within the exon 2 deletion
region that would act on genes 39 to Nfia, which exhibit
conservation of synteny between mouse and human. How-
ever, the genes immediately neighboring NFIA are not known
to play a role in CNS or kidney development. These include
C1orf87 (GeneID 127795) and TM2D1 (beta amyloid binding
protein, GeneID 83941), which reside approximately 1 Mb 59
and 200 kb 39 of NFIA, respectively. Additional genes that
reside at larger distances from NFIA might be affected by a
position effect, but none are obvious candidates. Taking these
factors into consideration, we conclude that a true position
effect is unlikely to explain the observed phenotypes.
Nature of the CNS Phenotype
Formation of the corpus callosum causes inversion of the
cingulate gyri, which gives the medial surface of the brain its
characteristic pattern. In ACC, the cingulum remains everted
at sites of agenesis, and the sulci of the medial brain extend
into the third ventricle. The findings in DGAP174 of an
everted cingulate gyrus and longitudinal bundles of Probst
are consistent with primary dysgenesis of the corpus
callosum. Three midline populations contribute to formation
of the corpus callosum: the glial sling, the glial wedge, and glia
within the indusium griseum and its precallosal extension,
the hippocampal continuation [39–41]. NFIA protein is
expressed in all three midline populations, which fail to
develop properly in Nfia/ mice [34]. These populations
normally form the corticoseptal boundary that prevents
callosal axons from entering the septum.
The function of NFIA in formation of these neuronal
populations places it within the class of genes that regulate
axonal midline crossing. The prototypical regulatory gene in
this class is roundabout or robo, which was originally identified
in Drosophila. Roundabout encodes a transmembrane receptor
expressed by migratory axons after they cross the CNS
midline. Robo binds the extracellular ligand, Slit, which is
expressed by midline glia and functions as a chemorepulsive
cue that prevents axons from midline recrossing. This
function extends to mammals, as mice lacking Robo1 or Robo2
exhibit CNS phenotypes that include abnormal midline
commissural axonal guidance, and Robo1 mutants in partic-
ular exhibit callosal dysgenesis [42,43]. Similarly, Slit ligands
also play a role in callosal development. Slit2 mutants display
a small corpus callosum with a reduced number of traversing
axons [44–46], while Slit2 glial expression during callosal
development in Nfia mutants is reduced [34].
Interestingly, Nfia, Robo2, and Slit2 mouse mutants share
not only axonal midline crossing defects, but also phenotypi-
cally related renal and ureteral defects. Mice deficient for
Robo2 or Slit2 exhibit duplex kidney and megaureter
phenotypes [32,47] that in some ways resemble those in Nfia
mutants. Our recent study also implicated ROBO2 signaling
in the pathogenesis of a subset of human VUR [32]. These
related phenotypes raise the possibility that Nfia and SLIT–
ROBO signaling are functionally linked in both CNS and
ureteral development.
Relationship between Kidney and Ureter Phenotypes
Based on Nfia expression in the developing kidney and the
presence of kidney hypoplasia in DGAP104, we identified
several distinct kidney phenotypes, including renal dysplasia
and hydronephrosis in Nfia mutant mice. Hydronephrosis
usually results from an obstruction in the flow of urine at the
level of the UPJ or UVJ. This results in an obstructive
uropathy in which back pressure from the accumulation of
urine in the ureter and renal pelvis results in destruction and
distortion of the renal parenchyma. The presence of hydro-
nephrosis in Nfia/ and Nfiaþ/ mutants therefore suggests
that the observed renal defects reflect a primary disturbance
in ureteral development.
A striking finding in Nfia mutant embryos and newborns is
the presence of clear ureteral abnormalities: megaureter,
abnormal ureteral folding, abnormalities at the UVJ and UPJ,
and in a small number of cases, partial duplication of the
ureter. These findings are consistent with the strong
expression of Nfia in the developing nephric duct and ureter
at E9.5–13.5. The ureteral duplication phenotype, distinct
from normal patterns of ureteric bud branching [48], very
likely explains the finding of a partial duplex kidney. Because
ureteric bud contact with uninduced metanephric mesen-
chyme triggers the inductive cascade [49], contact by two
separate ureteral branches should produce a partial duplex
kidney. In addition to abnormal ureteral development, the
VUR in DGAP104 and in the DGAP205 half-siblings may also
develop as a consequence of the tethered spinal cord defect
[50,51].
In DGAP089 and 174, renal ultrasound revealed no major
abnormalities and urinary reflux was not observed. However,
subtle anatomic defects in the ureter or kidney are often sub-
clinical, and may exist below the limit of detection. In
addition, these results are consistent with those in Nfiaþ/ and
Nfia/ mutants, where the penetrance of overt kidney or
ureteral defects was only 22% and 68%, respectively. One
explanation for the incomplete penetrance of ureteral or
kidney defects in Nfia mutants could be functional redun-
dancy with Nfib. In mice, Nfib is strongly expressed in the
developing nephric duct, kidney, and ureter at E10.5–11.5,
where its expression overlaps with that of Nfia (unpublished
data). The other two Nuclear Factor I family members, Nfic
and Nfix, are expressed only at lower levels in the developing
ureter and kidney. In addition, Nfib/ mice exhibit callosal
agenesis and forebrain defects similar to those seen in Nfia/
mice [21]. Thus, partial redundancy may exist between Nfia
and Nfib in both CNS and urinary tract development. Genetic
combinations of mutant alleles for Nfia and Nfib will be
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required to address this question definitively, and to further
disclose the roles of Nfi factors in development.
In sum, our results suggest that NFIA haploinsufficiency in
humans results in a thin, hypoplastic or absent corpus
callosum, and define the spectrum of defects attributable to
NFIA loss of function to include additional CNS and urinary
tract defects that were not previously apparent in the Nfia
mouse mutant. These results illustrate the powerful synergy
that occurs when corresponding human and mouse disorders
are investigated in parallel.
Materials and Methods
DGAP individuals studied. DGAP104. DGAP104 is the product of
in vitro fertilization via intracytoplasmic sperm injection, whose
parents of European descent were unrelated with no reported
medical problems. Amniocentesis demonstrated a 46,XX,t(1;20)
(p32.3;q13.31)dn, but ultrasound revealed no organ malformations
at 20 wk of pregnancy. Because of placenta previa and persistent
vaginal bleeding, DGAP104 was delivered at 31 wk via elective
cesarean section and weighed 1,980 g with Apgar scores of 9/10/10.
She was diagnosed with prematurity, hydrocephaly, Chiari I
malformation, tethered spinal cord, congenital hydronephrosis, left
hypoplastic kidney, bilateral inguinal hernia, hyaline membrane
disease grade 2, and gastroesophageal reflux. Imaging studies
indicated a thin posterior corpus callosum and an open aqueduct
with progressive ventricular enlargement. She was delayed in reach-
ing developmental milestones; at 2 y, she exhibited major motor delay
with inhibited movement and was wheelchair bound. Speech was also
delayed, and limited to a few words. At 6 y 7 mo of age, DGAP104
received a performance IQ score of 42, verbal IQ score of 68, and
global IQ score of 52 on the Weschler Preschool and Primary Scale of
Intelligence-Revised test (WPPSI-R).
To relieve hydrocephalus, which caused progressive macrocephaly,
seven neurosurgical operations were performed over 5 y, including a
third ventriculocisternostomy, a ventriculoperitoneal shunt with a
flow-regulated valve, and several revisions because of hyperdrainage
or blockage of the shunt. At 7 d of age, abdominal ultrasonography
revealed bilateral hypoplastic kidneys and bilateral dilatation of the
renal pelvis. At 1 y, ultrasound showed left and right kidney lengths of
45 mm and 51 mm, respectively (mean length for age, 52 mm), and
both kidneys lacked corticomedullary differentiation. At 2 y, the left
kidney length was 49 mm and the right 58 mm (mean length for age,
55 mm), but both lacked discernable corticomedullary differentia-
tion. At 5 y, the left kidney was 53 mm and the right 61 mm (mean
length for age, 66 mm). DGAP104 first exhibited left grade II VUR by
VCUG at 1 y. At 2 y, VUR increased to grade III with a right
vesicoureteral junction diverticulum, and pyelonephritis developed
that required ureteral reimplantation surgery (Cohen operation).
Urea and creatinine levels were normal at 5 y of age.
DGAP089. DGAP089 is a male with an interstitial deletion on 2q
and a balanced translocation involving 1p and 2q. Additional clinical
data are summarized in Table S1 and described in more detail
elsewhere [22]. Seizure onset occurred at 19 mo, with treatment until
age 6 y and no recurrences thereafter. He rolled to one side at 10 mo,
to either side at 14 mo, and sat at 14 mo. At 3 y, he received the Bayley
Scales of Infant Development test (2nd edition, BSID-II), and earned
a Mental Developmental Index (MDI) that fell below the standard
score of 50 with an age equivalent of 4 mo. He also received the
Vineland Adaptive Behavior Scales test (parent form VABS), and
obtained an adaptive behavior composite score of 45 corresponding
to an age equivalent of 7 mo. He cruised at 4 y, and walked at 5 y.
DGAP089 underwent a brain MRI at 6.5 y that revealed a hypoplastic
corpus callosum with enlarged frontal horns, parallel in configu-
ration, without evidence of increased intracranial pressure. The MRI
also showed polymicrogyria and an 8-mm nodule along the lateral
wall of the left frontal horn that likely represented a gray matter
heterotopia. Renal ultrasound performed at 6.5 y was normal. There
was no significant change in the physical examination and no focal
sensorimotor deficits were noted. When last examined at age 8 y
(2005), DGAP089 was no longer wearing leg braces, was able to walk
and run on his toes, and could eat table foods without difficulty, but
was not toilet trained. Speech consisted of about three words in
appropriate context, and he was being taught American Sign
Language (ASL). He could gesture, but was unable to follow
commands, and engaged in self-stimulatory behavior.
DGAP174. DGAP174 was born to a 20-y-old mother at 37 wk by
cesarean section and weighed 2,770 g (95th percentile) with length
49.5 cm (25th percentile) and occipitofrontal circumference 37.5 cm
(75th percentile). Pregnancy was uncomplicated by teratogenic
exposures or maternal illness. A second trimester prenatal ultrasound
showed agenesis of the corpus callosum and enlarged ventricles. A CT
scan of the brain in the immediate postnatal period confirmed the
prenatal findings, and revealed ventriculomegaly with parallel lateral
ventricles representing longitudinal bundles of Probst, and a tethered
spinal cord. A small ventricular septal defect was also noted at birth.
Chromosome analysis of peripheral blood lymphocytes revealed
46,XY,t(1;3)(p22;q21)dn. The neonate was discharged and seen again
at 13 d of age in the genetics clinic. He was found to have metopic
stenosis and bitemporal narrowing that was surgically corrected at 5
mo of age. Neurological exam revealed normal tone and reflexes. At 8
mo of age, he was noted to be gaining weight rapidly, unrelated to any
change in eating pattern. Follow-up at 12 mo revealed delay in gross
motor development, macrocephaly without hydrocephalus, and
height, weight, and length above the 95th percentile for his age.
Additionally, a dimple on the posterior aspect of the right helix,
creases behind each earlobe, and esotropia secondary to telecanthus
and epicanthal folds were noted. A left inguinal hernia was detected
at 24 mo. Also at 24 mo, glasses were prescribed to correct
hypertropia and strabismus, and all milestones were on track except
for speech. At 36 mo, expressive language was still delayed. Due to
macrosomia, the patient underwent bone age testing, which was age
appropriate. A brain MRI at 36 mo of age revealed Chiari I
malformation and dysplasia of the anterior aspect of the left
temporal fossa in addition to complete agenesis of the corpus
callosum. At 57 mo of age, DGAP174 underwent several devel-
opmental tests. His IQ score was 68 on a Leiter International
Performance Scale (LIPS) test, corresponding to an age equivalent of
36 mo. He received a standard score of 60 in the Peabody Picture
Vocabulary Test (Revised, Form M; PPVT-R) corresponding to an age
equivalent of 35 mo. His standard score for the Developmental Test
of Visual-Motor Integration (VMI) was 67, which also corresponded
to an age equivalent of 35 mo. At 6 y of age, he underwent a successful
Chiari decompression and repair of the tethered spinal cord. At that
time, he was diagnosed with attention deficit and hyperactivity
disorder and is currently on Ritalin. He was noted to have right
hemihypertrophy and scoliosis, for which he was referred to an
orthopedics clinic. At age 8 y and 4 mo (January 2007), DGAP174 was
functioning at the kindergarten level, and received occupational and
physical therapy for speech.
DGAP205–1, 205–1s, and 205–2. DGAP205–1 and DGAP205-1s are
two half-siblings with an interstitial microdeletion, del(1)(p31.3p32.3),
that was inherited as an unbalanced segregant resulting from a
balanced rearrangement in their mother, DGAP205–2. Both half-
siblings had congenital CNS and urinary tract defects while their
mother was phenotypically normal. DGAP205–1 had the Bayley Scales
of Infant Development test (BSID) at 4.5 y of age and received scores
corresponding to an age equivalent of 18 mo for overall development,
20 mo for cognition, and 17 mo for fine motor. At age 5 y, DGAP205–
1 was functioning at an age equivalent of ;2.5 y. At age 10 y he was
functioning at an age equivalent of;7 y, and was 4 ft tall and weighed
;65 lb. DGAP205–1 has limited verbal skills and uses a combination
of words and signs for communication. He has not had any formal
testing at 10 y of age, but can only read and spell three-letter words.
DGAP205-1s received the Bayley Scales of Infant Development test
(BSID) at 2 y of age, and the Stanford-Binet test at 9 y. Both tests
demonstrated moderate global cognitive impairment (scores not
available). At 9 y of age, she was functioning academically at a
kindergarten level. Other clinical data for the affected sibs are
summarized in Table S1, and described in more detail elsewhere [23].
FISH, aCGH, and mutation screening. Metaphase FISH was
performed according to standard methods. BAC clones were
obtained from BAC/PAC Resources (http://bacpac.chori.org), labeled
as FISH probes, and hybridized to metaphase chromosomes prepared
from lymphoblastoid cell lines established from all five individuals.
The full BAC names provided in Figure 2I are: RP4-654H19, RP11-
55M23, RP5-829C20, RP11-13N22, RP4-802A10, RP4-662P1, RP5-
1078M7, RP4-534K7, RP11-86K19, RP11-131O15, and RP11-89K2.
aCGH experiments were performed with the Spectral Genomics 2600
BAC array by the Cytogenetics Core Facility of the Dana-Farber/
Harvard Cancer Center for DGAP089 and DGAP174, and by Spectral
Genomics for DGAP104. NFIA mutation screening employed PCR
amplification of the 11 human NFIA exons and intron-exon
boundaries, followed by purification and bidirectional DNA sequenc-
ing. NFIA cDNA sequence AB037860 (http://www.ncbi.nlm.nih.gov/
entrez/viewer.fcgi?db¼nucleotide&val¼7243275) was used to calculate
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nucleotide positions. MLPA analysis of the NFIA coding region was
performed in a subset of syndromic and nonsyndromic ACC samples,
and no copy number changes were identified.
RT-PCR analysis. RT-PCR analyses were performed by routine
protocols. RT-PCR primers used to amplify the Nfia 334 bp cDNA
were mNfia-rt-F (59-CAAGCCTCCAACCACATCAAC-39) and mNfia-rt-
R (59-CTGTTTGACCACGATGTTTGCT-39). RT-PCR primers used to
amplify the C20orf32 436 bp cDNA were mC20orf32-F (59-
GGGCACTCTACGACAACCAT-39) and mC20orf32-R: (59-
TCTGGGAAGCACAGAGAGG-39).
Southern and nothern blot analysis. Southern blotting was
performed by standard methods. Probes were labeled using the
MegaPrime labeling kit (Amersham/GE Healthcare, http://www.
amershamhealth-us.com). Genomic DNA from the DGAP089 cell
line and from a karyotypically normal control were digested with
DraII, PstI, and SspI and hybridized with a 700-bp probe ampli-
fied from RP5-902P15. This probe (AL096888; 66436–67143) was
amplified by the following primers: forward primer: 59-
CAGGCTTCTTCCCTCACAAG39 and reverse primer: 59-
GGTCCTTTCACGTGCATCTT-39. Southern blots of BpmI, BspHI,
DraII, EcoRI, HindIII, PvuII, and XhoI-digested DNA from DGAP104
and genomic DNA from a karyotypically normal male control were
hybridized with a 623-bp probe that was amplified from RP4-802A10
(AC096947.2; 50191–50687). This probe was amplified by the follow-
ing primers: forward primer: 59-AGGCACCAGGGCAGTAATC-39 and
reverse primer: 59-TAAGAACTCCAACCCCAGCA-39. A northern
blot containing poly Aþ RNA from multiple regions of human brain
(Human Brain V blot, Clontech, http://www.clontech.com) was
hybridized with a probe corresponding to exons 2–6 of NFIA
following a standard protocol.
Analysis of Nfia mutant mice. The generation and analysis of brain
defects in Nfia knockout mice in a C57BL/6 background has been
previously described [18]. Nfia/ mice analyzed in Figure S6 were
C57BL/6X129S6 F1 hybrid anaimals that have longer postnatal
survival than C57BL/6 inbred mice. The Nfia allele was genotyped
by PCR amplification using the mutant allele specific forward primer
Nfia-ln1-F2 (59-CGTGAGCTGGTACAGTTTGCA-39, in the non-de-
leted region of Nfia intron 1) and reverse primer Nfia-Neo-R2 (59-
GCCTGAAGAACGAGATCAGCA-39, in the neomycin selection cas-
sette). The Nfia wild-type allele was genotyped using the same forward
primer Nfia-ln1-F2 and a gene-specific reverse primer Nfia-WT-R2
(59-TGTTTGAGAATCTTTCTTCCTTTGG-39, in the deleted region
of Nfia intron 1). Histological analyses were performed on mouse
specimens fixed in 4% paraformaldehyde, embedded in paraffin,
sectioned at 4 lm, and stained with hematoxylin and eosin. To
examine ureter and kidney defects, Hoxb7-GFP transgenic mice (gift
from Dr. Frank Costantini, Columbia University) were bred with Nfia
knockout mutants. GFP fluorescence illumination of the mouse
urinary tract was evaluated using a Nikon SMZ-1500 epi-fluorescence
stereomicroscope (http://www.nikonusa.com).
In situ hybridization and immunohistochemistry. Tissue in situ
hybridization of whole mount and cryosections was performed
according to standard protocols using cRNA probes complementary
to the 39-UTRs of Nfia and C20orf32. For WT1 immunostaining,
kidney samples were fixed in 4% paraformaldehyde for 30 min and
embedded in OCT Compound. Tissues were then cryosectioned at 10
lm and stained with anti-WT1 antibody (Santa Cruz Biotechnology,
http://www.scbt.com). Dolichos Biflorus Agglutinin (DBA; Vector
Labs, http://www.vectorlabs.com) and Lotus Tetragonolobus Lectin
(LTL; Vector Labs) stainings were performed on paraffin-embedded
kidney sections.
Ethics. All human studies were performed under informed consent
protocols approved by the Human Research Committee of Partners
HealthCare System, Boston. Mouse protocols were approved by the
Institutional Animal Care and Use Committee at Harvard Medical
School or at Boston University Medical Center.
Supporting Information
Figure S1. Southern Blot Analysis of 1p31.3 Breakpoint in DGAP104
NFIA is disrupted in DGAP104 and the breakpoint lies within in-
tron 2.
(A) Southern blot analysis of DGAP104 (P) and normal control (C)
genomic DNA using the designated restriction enzymes and the
probe A4 shown in panel B. Aberrant bands (arrows in A) are present
only in DGAP104 DNA digested with BpmI, BspHI, DraII, EcoRI, and
XhoI.
(B) Restriction map surrounding the NFIA intron 2 region. The
base-pair position of BAC RP4-802A10 (AC096947, within intron 2
of NFIA, see BAC contig in Fig. 2I) was used to calculate the distance
between restriction enzyme sites. BAC RP4-802A10 was used in
FISH and contains the breakpoint, which is between boxed PvuII
and BpmI sites based on the aberrant bands detected by Southern
blot analysis.
Found at doi:10.1371/journal.pgen.0030080.sg001 (167 KB PDF).
Figure S2. In Situ Hybridization of Mouse C20orf32
C20orf32 is not expressed in the mouse embryonic spinal cord and
kidney at E10.5 and E11.5.
Found at doi:10.1371/journal.pgen.0030080.sg002 (33 KB PDF).
Figure S3. Southern Blot Analysis of 1p31.3 Breakpoint in DGAP089
NFIA is disrupted in DGAP089 and the breakpoint lies within
intron 7.
(A) Southern blot analysis of DGAP089 (P) and normal control (C)
genomic DNA using the designated restriction enzymes and the
probe A1 shown in panel B. Aberrant bands (arrows in A) are present
in DGAP089 DNA digested with DraII, PstI and SspI.
(B) Restriction map surrounding the NFIA intron 7 region. The
base-pair position of BAC RP5-902P15 (AL096888, within intron 7
of NFIA, see BAC contig in Fig. 2I) was used to calculate the distance
between restriction enzyme sites. BAC RP5-902P15 was used in FISH
and contains the breakpoint, which is between boxed SspI and DraII
sites based on the aberrant bands detected by Southern blot
analysis.
Found at doi:10.1371/journal.pgen.0030080.sg003 (104 KB PDF).
Figure S4. Array Comparative Genomic Hybridization (aCGH) for
DGAP174
Array CGH at a 1-Mb resolution defines the deletion interval in
DGAP174. Spectral Genomics profile indicates the deletion interval
(arrow) on 1p from 1p32.1 to 1p31.3.
Found at doi:10.1371/journal.pgen.0030080.sg004 (131 KB PDF).
Figure S5. Northern Blot Analysis of NFIA in Different Regions of the
Human Brain
Northern blot of multiple human brain tissues was hybridized with a
probe containing NFIA exons 2–6.
Found at doi:10.1371/journal.pgen.0030080.sg005 (109 KB PDF).
Figure S6. Hydronephrosis in P16 Nfia/ Mutant
Severe hydronephrosis (* in B) is shown in a P16 Nfia/ mutant
kidney, whereas the kidney in its wild-type littermate (A) is normal.
Found at doi:10.1371/journal.pgen.0030080.sg006 (94 KB PDF).
Table S1. Clinical Findings in Five Individuals with Chromosome
Abnormalities Involving 1p31
Found at doi:10.1371/journal.pgen.0030080.st001 (61 KB DOC).
Table S2. Phenotypes of 84 Patients with Callosal and other CNS
Malformations and Urinary Tract Defects Subjected to NFIA Intra-
genic Mutation Screening
Found at doi:10.1371/journal.pgen.0030080.st002 (144 KB DOC).
Accession Numbers
The GeneID numbers for the Entrez Genes (http://www.ncbi.nlm.nih.
gov/entrez/query.fcgi?db¼gene) discussed in this paper are: AK3L2
(387851), ALG6 (29929), ANGPTL3 (27329), ANKRD38 (163782),
ATG4C (84938), BSND (7809), C1orf87 (127795), C1orf141 (400757),
C1orf168 (199920), C8A (731), C8B (732), C20orf32 (57091), C20orf32
(320664), CACHD1 (57685), CYP2J2 (1573), DAB1 (1600), DNAJC6
(9829), DOCK7 (85440), FLJ10986 (55277), FLJ45337 (400754), FOXD3
(27022), HOOK1 (51361), IL23R (149233), INADL (10207), INSL5
(10022), ITGB3BP (23421), JAK1 (3716), JUN (3725), KIAA1799 (84455),
L1TD1 (54596), LEPR (3953), LEPROT (54741), MIER1 (57708),
NEGR1 (257194), NFIA (4774), Nfia (18027), OMA1 (115209), PCSK9
(255738), PDE4B (5142), PGM1 (5236), PPAP2B (8613), PRKAA2 (5563),
RAVER2 (55225), ROR1 (4919), SGIP1 (84251), SLC35D1 (23169),
TACSTD2 (4070), TCTEX1D1 (200132), TM2D1 (83941), UBE2U
(148581), USP1 (7398), and WDR78 (79819).
The disease identifiers for the OMIM (http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?db¼OMIM) genetic disorders discussed in this paper
are: agenesis of the corpus callosum (OMIM 217990), hydrocephalus
and ventriculomegaly (OMIM 236600), Chiari malformation type I
(OMIM 118420), and vesicoureteral reflux (OMIM 193000 and
610878).
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